- Home
- POAI vs MYNZ Comparison
POAI vs MYNZ Comparison
Compare POAI & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POAI
- MYNZ
- Stock Information
- Founded
- POAI 2002
- MYNZ 2021
- Country
- POAI United States
- MYNZ Germany
- Employees
- POAI N/A
- MYNZ N/A
- Industry
- POAI Industrial Specialties
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- POAI Health Care
- MYNZ Health Care
- Exchange
- POAI Nasdaq
- MYNZ Nasdaq
- Market Cap
- POAI 8.9M
- MYNZ 8.0M
- IPO Year
- POAI N/A
- MYNZ 2021
- Fundamental
- Price
- POAI $0.94
- MYNZ $2.08
- Analyst Decision
- POAI Hold
- MYNZ Buy
- Analyst Count
- POAI 1
- MYNZ 2
- Target Price
- POAI N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- POAI 230.6K
- MYNZ 92.3K
- Earning Date
- POAI 05-15-2025
- MYNZ 06-17-2025
- Dividend Yield
- POAI N/A
- MYNZ N/A
- EPS Growth
- POAI N/A
- MYNZ N/A
- EPS
- POAI N/A
- MYNZ N/A
- Revenue
- POAI $1,729,269.00
- MYNZ $893,991.00
- Revenue This Year
- POAI $486.27
- MYNZ $26.06
- Revenue Next Year
- POAI $65.50
- MYNZ $4.97
- P/E Ratio
- POAI N/A
- MYNZ N/A
- Revenue Growth
- POAI 24.17
- MYNZ N/A
- 52 Week Low
- POAI $0.55
- MYNZ $1.92
- 52 Week High
- POAI $3.06
- MYNZ $34.00
- Technical
- Relative Strength Index (RSI)
- POAI 43.21
- MYNZ 38.07
- Support Level
- POAI $0.92
- MYNZ $1.93
- Resistance Level
- POAI $0.99
- MYNZ $2.10
- Average True Range (ATR)
- POAI 0.08
- MYNZ 0.16
- MACD
- POAI -0.00
- MYNZ 0.04
- Stochastic Oscillator
- POAI 24.13
- MYNZ 30.39
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.